TCR-Based Antigen-Specific Therapy for Type 1 Diabetes Mellitus: From Editing Autoreactive Clones to Tolerance Induction
International Journal of Molecular Sciences · 28.11.2025 · 26 (23) · 11563
DOI: 10.3390/ijms262311563 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.11.2025. Verfasst von Marina Fisher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Receptors, Antigen, T-Cell, Immune Tolerance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by the destruction of insulin-producing pancreatic β-cells by autoreactive T cells. Current treatments, including insulin replacement therapy and various immunotherapies, often modulate but fail to permanently halt the underlying autoimmune process or restore β-cell function. In this review, we examine T cell receptor (TCR)-based treatment strategies for T1DM. We focus on two main approaches: selective elimination of pathogenic autoreactive T cell clones and induction of immune tolerance using TCR-modified regulatory T cells (TCR-Tregs). We describe key islet autoantigens, including post-translationally modified neoantigens such as fusion insulin peptides, which are crucial for identifying pathogenic TCRs. Next, we will review methodologies for TCR detection and TCR-Treg generation, highlighting their mechanisms of action and impact on various immune cells, including dendritic cells, B cells, and macrophages. We will also examine the potential of CD8+T cell regulatory cells (CD8+Tregs). Finally, we will discuss the future of TCR-based therapy, emphasizing the need to optimize TCR affinity, ensure Tregs’ stability, and develop combination therapies. TCR-based therapy represents a revolutionary approach to restoring immune tolerance in T1DM, providing high specificity and reducing the risk of systemic immuno-suppression compared to traditional treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.
ORCID-Profile: Marina Fisher, Sergey Sennikov
Förderung
- Russian Science Foundation
Zitieren
APA
Fisher, M., Philippova, J., Kurilin, V., & Sennikov, S. (2025). TCR-Based Antigen-Specific Therapy for Type 1 Diabetes Mellitus: From Editing Autoreactive Clones to Tolerance Induction. International Journal of Molecular Sciences, 26(23), 11563. https://doi.org/10.3390/ijms262311563
Vancouver
Fisher M, Philippova J, Kurilin V, Sennikov S. TCR-Based Antigen-Specific Therapy for Type 1 Diabetes Mellitus: From Editing Autoreactive Clones to Tolerance Induction. International Journal of Molecular Sciences. 2025;26(23):11563. doi:10.3390/ijms262311563
BibTeX
@article{Fisher2025,
author = {Fisher, Marina and Philippova, Julia and Kurilin, Vasily and Sennikov, Sergey},
title = {TCR-Based Antigen-Specific Therapy for Type 1 Diabetes Mellitus: From Editing Autoreactive Clones to Tolerance Induction},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {23},
pages = {11563},
doi = {10.3390/ijms262311563}
}
EUVIMED